Aberdeen Group plc and its U.S. subsidiary abrdn Inc. filed an amended beneficial ownership statement with the SEC on October 29, 2026, disclosing a combined 484,887-share position in Tectonic Therapeutic, Inc. as of September 30, 2026.

Key Highlights

  • Filing date: October 29, 2026, reflecting ownership as of September 30, 2026
  • Shares reported: 484,887 shares of Common Stock, $0.0001 par value per share (CUSIP 878972108)
  • Percent of class: 2.48% of outstanding shares, confirmed as 5% or less of class
  • Shared voting and dispositive power: Both Aberdeen Group plc and abrdn Inc. each report 484,887 shares with shared voting and shared dispositive power; neither holds sole voting or sole dispositive power
  • Reporting entities: Aberdeen Group plc (United Kingdom) is identified as the parent holding company; abrdn Inc. (United States) is the subsidiary investment adviser that beneficially owns the shares on behalf of underlying clients
  • Amendment: This filing is designated Amendment No. 1 to a prior statement

Aberdeen Group and abrdn Inc. Disclose Combined Position in Tectonic Therapeutic

According to the filing, Aberdeen Group plc, headquartered at 1 George Street, Edinburgh, United Kingdom, and its U.S.-based subsidiary abrdn Inc., located at 1900 Market Street Suite 200, Philadelphia, PA 19103, jointly report beneficial ownership of 484,887 shares of Common Stock in Tectonic Therapeutic, Inc., a biopharmaceutical company incorporated in Delaware and headquartered at 490 Arsenal Way, Suite 210, Watertown, Massachusetts 02472. The shares are identified under CUSIP number 878972108 and trade on NASDAQ:TECX. The filing is an amendment to a previously submitted statement, with the triggering event date cited as September 30, 2026.

The filing states that abrdn Inc. "beneficially owns on behalf of our underlying clients less than 5% of the outstanding shares of the security class being reported." Aberdeen Group plc is identified as the parent holding company, with abrdn Holdings Limited listed as an intermediate holding company for abrdn Inc. For both reporting persons, sole voting power and sole dispositive power are each listed as zero, while shared voting power and shared dispositive power are each recorded at 484,887 shares. The combined stake represents 2.48% of the class, which the filing confirms falls within the "ownership of 5 percent or less of a class" threshold under Item 5.

The filing was signed by Romiza Chaudhry, identified as Major Shareholding Reporting Analyst, on behalf of both Aberdeen Group plc and abrdn Inc. on October 29, 2026. The certifications in the filing state that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

Aberdeen Group plc and abrdn Inc. reported an aggregate beneficial ownership of 484,887 shares, equal to 2.48% of Tectonic Therapeutic, Inc.'s outstanding common stock, held entirely through shared voting and shared dispositive power as of September 30, 2026.